Related Experiment Videos
Insulin in type 2 diabetes: promises to keep
A K Basu1, D Bandyopadhyay, R Bandyopadhyay
1Department of Medicine, Medical College, Kolkata 700073.
Journal of the Indian Medical Association
|February 22, 2005
Summary
Early insulin therapy for type 2 diabetes mellitus preserves beta-cell function, improving glycemic control and reducing hypoglycemia risk. This approach utilizes advanced insulin analogues for better patient outcomes.
Area of Science:
- Endocrinology
- Metabolic Diseases
- Pharmacology
Background:
- Type 2 diabetes mellitus (T2DM) management has evolved towards early insulin intervention.
- T2DM is characterized by impaired first-phase insulin response and eventual beta-cell exhaustion.
- Conventional treatment often delays insulin initiation until beta-cells are severely compromised.
Purpose of the Study:
- To highlight the benefits of early insulin therapy in T2DM.
- To emphasize the role of preserving beta-cell function.
- To discuss the use of insulin analogues for optimized glycemic control.
Main Methods:
- Conceptual review of T2DM pathophysiology and management strategies.
- Discussion of beta-cell function preservation through early insulin use.
- Exploration of insulin analogues (designer insulins) for improved therapeutic action.
Main Results:
- Early insulin therapy preserves beta-cell function, leading to better glycemic control.
- Patients experience improved glycemic control with lower medication doses.
- Preserved glucagon response contributes to a relative freedom from hypoglycemia.
Conclusions:
- Early insulin therapy is a key strategy in T2DM management.
- Preserving beta-cell function offers significant clinical advantages.
- Optimized glycemic control from diagnosis favorably impacts morbidity and mortality in T2DM.